Hista-Aid References

Revised References List HistaAid

1. Pawanker R, Canonica GW et al. White Book on Allergy 2011-2012 Executive Summary. World Health Organization.
2. Allergy Overview. Asthma and Allergy Foundation of America. https://www.aafa.org/allergies/. Reviewed September 2015. Accessed September 2022.
3. Gupta RS, Warren CM et al. Prevalence and severity of food allergies among US adults. JAMA Netw Open. 2019 Jan 4; 2(1): e18563
4. Simons FE, Simons KJ. H1 antihistamines: current status and future directions. World Allergy Organ J. 2008; 1(9): 145-55.
5. Greaves MW, Sabroe RA. Histamine: the quintessential mediator. J Dermatol. 1996; 23(11): 735-40.
6. Fersti R, Akdis C et al. Histamine regulation of innate and adaptive immunity. Front Biosci (Landmark Ed). 2012; 17: 40-53.
7. Benarroch EE. Histamine in the CNS: multiple functions and potential neurologic implications. Neurology. 2010; 75(16): 1472-9.
8. Vasoactive Amines. Available at: https://vet.uga.edu/ivcvm/courses/VPAT5200/03_inflammation/04_cmi/cmim02.htm (Accessed June 23, 2019).
9. Parsons ME, Ganellin CR. Histamine and its receptors. Br J Pharmacol. 2006; 147 Suppl 1(Suppl 1): S127–S135.
10. Krystel-Whittemore M, Dileepan KN et al. Mast Cell: a multi-functional master cell. Front Immunol. 2016; 6: 620.
11. Pinzer TC, Tietz E et al. Circadian profiling reveals higher histamine plasma levels and lower diamine oxidase serum activities in 24% of patients with suspected histamine intolerance compared to food allergy and controls. Allergy. 2018; 73(4): 949–957.
12. Maintz L, Novak N. Histamine and histamine intolerance. Am J Clin Nutr. 2007; 85(5): 1185-96.
13. Frieri M, Patel R et al. Mast cell activation syndrome: a review. Curr Allergy Asthma Rep. 2013 Feb;13(1):27-32
14. Cingi C, Gevaert P et al. Multi-morbidities of allergic rhinitis in adults: European Academy of Allergy and Clinical Immunology Task Force Report. Clin Transl Allergy. 2017; 7: 17.
15. Gough H, Grabenhenrich L et al. Allergic multimorbidity of asthma, rhinitis and eczema over 20 years in the German birth cohort MAS. Pediatr Allergy Immunol. 2015;26(5):431–437.
16. Micek J, Jurkova T et al. Quercetin and its anti-allergic immune response. Molecules. 2016; 21(5).
17. Ueda H, Yamazaki C. Luteolin as an anti-inflammatory and anti-allergic constituent of Perilla frutescens. Biol Pharm Bull. 2002; 25(9): 1197-202.
18. Amellal M, Bronner C et al. Inhibition of mast cell histamine release by flavonoids and biflavonoids. Planta Med. 1980; 51(1): 16-20.
19. September-Malaterre A et al. Focus on the high therapeutic potentials of quercetin and its derivatives. Phytomedicine Plus. 2022; 2(1): 100220.
20. Giminez-Bastida JA et al. Targeting mammalian 5-lipoxygenase by dietary phenolics as an anti-inflammatory mechanism: A systematic review. Int J Mol Sci. 2021; 22(15): 7937.
21. Karuppagounder V, Arumugam S. Molecular targets of quercetin with anti-inflammatory properties in atopic dermatitis. Drug Discov Today. 2016; 21(4): 632-9.
22. Kimata M, Inagaki N et al. Effects of luteolin and other flavonoids on IgE-mediated allergic reactions. Planta Med. 2000; 66(1): 25-9
23. Kempuraj D, Tagen M et al. Luteolin inhibits myelin basic protein-induced human mast cell activation and mast cell dependent stimulation of Jurkat T cells. Br J Pharmacol. 2008; 155: 1076–84.
24. Kimata M, Shichijo et al. Effects of luteolin, quercetin and baicalein on immunoglobulin E-mediated mediator release from human cultured mast cells. Clin Exp Allergy. 2000; 30:501–8.
25. Seelinger G, Merfort I et al. Anti-oxidant, anti-inflammatory and antiallergic activities of luteolin. Planta Med. 2008: 74, 1667–1677.
26. Kazmierczak-Baranska J et al. Two faces of vitamin C—antioxidative and pro-oxidative agent. Nutrients. 2020; 12(5): 1501.
27. Hagel AF, Layritz CM. Intravenous infusion of ascorbic acid decreases serum histamine concentrations in patients with allergic and non-allergic diseases. Naunyn Schmiedebergs Arch Pharmacol. 2013; 386: 789-793.
28. Jarisch R et al. Influence of orally taken vitamin C on histamine levels and motion sickness.
29. Jiang L, Diaz PT et al. Molecular characterization of redox mechanisms in allergic asthma. Ann Allergy Asthma Immunol. 2014; 113: 137–142.
30. Fogarty A, Lewis SA et al. Corticosteroid sparing effects of vitamin C and magnesium in asthma: a randomized trial. Respir Med. 2006; 100(1): 174-179.
31. Vollbracht C, Rathel M. Intravenous vitamin C in the treatment of allergies: an interim subgroup analysis of a long-term observational study J Int Med Res. 2018; 46(9): 3640-3655.
32. Hagel AF, Layritz CM et al. Intravenous infusion of ascorbic acid decreases serum histamine concentrations in patients with allergic and non-allergic diseases. Arch Pharmacol. 2013; 386: 789–793.
33. Keum YS. Regulation of Nrf2-mediated phase II detoxification and anti-oxidant genes. Biomol Ther (Seoul). 2012; 20(2): 144-151.
34. Hu B et al. Nuclear factor E2 related factor (NRF2) inhibits mast cell-mediated allergic inflammation via SIRT4-mediated mitochondrial metabolism. Annals of Palliative Medicine. 2020; 9(6).
35. Rajora S, Suriano R. et al. 3,30 -Diindolylmethane modulates estrogen metabolism in patients with thyroid proliferative disease: a pilot study. Thyroid. 2011(21): 3; 299-304.
36. Bonds RS, Midoro-Horiuti T. Estrogen effects in allergy and asthma. Curr Opin Allergy Clin Immunol. 2013; 13(1): 92–99.
37.  Zierau O, Zenclussen AC et al. Role of female sex hormones, estradiol, and progesterone, in mast cell behavior. Front Immunol. 2012; 3: 169. 
38. Bódis J1, Tinneberg HR et al. The effect of histamine on progesterone and estradiol secretion of human granulosa cells in serum-free culture. Gynecol Endocrinol. 1993; 7(4): 235-9.  
39. Ernst IM, Schuemann C et al. 3,3′-Diindolylmethane but not indole-3-carbinol activates Nrf2 and induces Nrf2 target gene expression in cultured murine fibroblasts. Free Radic Res. 2011; 45(8): 941-9. 
40. Anderton MJ, Manson MM et al. Physiological modeling of formulated and crystalline 3,3′-diindolylmethane pharmacokinetics following oral administration in mice. Drug Metab Dispos. 2004 Jun;32(6):632-8. 
41. Shiue I. Is abnormal liver function correlated with food sensitization in adults? US NHANES, 2005–2006. Allergol Immunopathol. 2015; 43(4): 361-368.
42. Ferreira-Silva M, et al. Quercetin Liposomal nanoformulation for ischemia and reperfusion injury treatment. Pharmaceutics. 2022; 14(1): 104.
43. Taheri Y, et al. Paving luteolin therapeutic potentialities and agro-food-pharma applications: emphasis on in vivo pharmacological effects and bioavailability traits. Oxid Med Cell Longev. 2021; 1987588.  
44. Gopi S and Balakrishnan P. Evaluation and clinical comparison studies on liposomal and non-liposomal ascorbic acid (vitamin C) and their enhanced bioavailability. J Liposome Res. 2020; 356-364.